MTMR12

Across TCGA pan-cancer cohorts, MTMR12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTMR12 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTMR12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTMR12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where MTMR12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.894	0.477	.002	65	view →
PDAC	DFS	Tertile	II,III,IV	0.508	0.270	.003	34	view →
LSCC	DFS	Median	All	0.897	0.975	.002	11	view →
LUAD	DFS	Median	All	0.735	0.505	.014	6	view →
UCEC	OS	Median	III,IV	0.554	0.884	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTMR12–CCRCC (DFS)

Open the CCRCC breakdown →